Where is the US Hepatitis C Epidemic *Now*? Putting the “Pen” on the Map as Elimination Efforts Hunt for Remaining Cases.

Anne Spaulding, Emory University
CAT Vidarte
EJ Anderson
MA Khan
JA Phillips

Journal Title: Open Forum Infectious Diseases
Volume: Volume 4, Number suppl_1
Publisher: (publisher) | 2017, Pages S195-S195
Type of Work: Article
Publisher DOI: 10.1093/ofid/ofx163.372
Permanent URL: https://pid.emory.edu/ark:/25593/s6g5b

Final published version: http://dx.doi.org/10.1093/ofid/ofx163.372

Accessed December 13, 2017 9:21 AM EST

Anuj Patel, MD1; Richard Rothman, MD, PhD1; David Thomas, MD, MPH, FIDSA2; and Yu-Hsiang Hsieh, PhD3; 1Emergency Medicine, Johns Hopkins University, Baltimore, Maryland, 2Johns Hopkins University School of Medicine, Baltimore, Maryland, 3Johns Hopkins University School of Medicine, Baltimore, Maryland

Session: 59. Hepatitis B and C in Varied Settings
Thursday, October 5, 2017: 12:30 PM

**Background.** CDC estimated 30,500 new HCV infections in the US in 2014 (or 0.096 per 1,000 person-years (PYs)) and HCV incidence of high-risk groups ranged from 2 to 400 per 1000 PYs. High seroprevalence of HCV antibody, evidence of HCV infection ever, is common among urban emergency department (ED) patients. Little is known regarding incidence of HCV infection in urban ED patients in recent years.

**Methods.** We conducted a retrospective cohort study to determine HCV incidence among ED adult patients. The study ED rolled out an ED-based HCV screening program since November 2015. A secondary data analysis was performed from a seroprevalence study on all adult patients who visited the study ED during December 10, 2015 and January 21, 2016. Patients who had at least two HCV antibody tests from two separate visits at the study hospital from 2003 to 2016 were included for this secondary data analysis. Patients who had reactive HCV antibody result at the first time point were excluded. Follow-up time (PYs) was calculated for each patient by the interval of between two HCV antibody tests. Time of HCV seroconversion was defined as the midpoint between the negative and positive HCV antibody test. Incidence rate ratio (IRR) and corresponding 95% CI was used to present the relative incidence between groups by mid-p exact test.

**Results.** A total of 302 ED patients were identified. The majority of them were female (60%), African American (79%), aged 35 years and older (60%). Sixty-eight percent of patients were born after 1965 (68%) and 25% born between 1945 and 1965 (birth cohort). Fifty-six percent of patients had commercial insurance payer and 36% had Medicaid or Medicare. Thirty-four (11%) patients had HIV infection and 7 (2%) were injection drug users (IDU). Overall, 6 (2%) had HCV seroconversion during 971.1 PYs, resulting in an HCV incidence of 6.2 per 1,000 PYs (95% CI: 2.5, 12.9 per 1,000 PYs). The incidence was significantly different by race [white: 30.9/1,000 PYs, African America: 2.9/1,000 PYs; RR: 12.3 (2.2, 95.8)] and IDU (IDU: 193/3,100 PYs, non-IDU: 42/1,000 PYs; RR: 46.2 (5.9, 260.3)) but not by birth cohort or HIV status.

**Conclusion.** The HCV incidence in urban ED patients was over 60 times higher than the general US population and even higher in some high-risk groups, indicating ED is a critical venue for identifying high-risk individuals for HCV prevention and detecting HCV-infected Americans for treatment.

**Disclosures.** All authors: No reported disclosures.

515. Where is the US Hepatitis C Epidemic *Now*? Putting the “Pen” on the Map of HCV Infection prevalence nationwide, which varies by state and time. Better checks for uni -

Disclosures. A. C. Spaulding, Gilead Science: Grant Investigator and Scientific Advisor, Consulting fee and Research grant.

516. African-Born Status and Risk of Hepatocellular Carcinoma among Patients with Chronic Hepatitis B Infection

Kaitlyn Kennedy, BA1; Nayan Arora, MD1; Susan Graham, MD; MPH; PhD2 and H. Nina Kim, MD, MSc2; 1University of Washington, Seattle, Washington, 2Medicine, University of Washington, Seattle, Washington

Session: 59. Hepatitis B and C in Varied Settings
Thursday, October 5, 2017: 12:30 PM

**Background.** Hepatitis C disease (hepC) is unevenly distributed both by geography and subpopulation. Our 2013 US prisons survey led to an estimate of 17.4% anti-HCV prevalence in state prison populations. The 10M persons who pass through jails and prisons each year bear 30–50% of disease burden, but are excluded from traditional sources of surveillance data, such as NHANES. CDC estimates 50% of persons with hepC lack knowledge of infection in life, thus death data are also imperfect. Data for corrections would enrich understanding of geographic representation of hepC.

**Methods.** In 11/2016, we surveyed state prison medical directors, providers and testers, for data on non-targeted screening of prisoners between 2010-2016. Non-responders were phoned for information. Sizes of state prison populations came from the Bureau of Justice Statistics. Via published reports, we obtained data on jail prevalence. Estimates of the contribution to the national hepC in prison epidemic came from weighting the size of the prison population of the states with infection ever, is common among urban emergency department (ED) patients. Little is known regarding incidence of HCV infection in urban ED patients in recent years.

Data from penitentiaries allow us to estimate an 18% prison anti- HCV prevalence nationwide, which varies by state and time. Better checks for uniformity in reporting in the future, such as how known positives are handled, would improve data quality. Correctional systems that routinely screen provide real-time data on new trends in hepC distribution, which will help ongoing efforts to treat and eliminate hepC. Such data could improve estimates based on NHANES and death data. Over 99% of persons entering jails and prisons leave, so the correctional epidemic closely influences the community epidemic. Adding hepC data from the Federal Bureau of Prisons, which tests persons entering from every state, will further inform our understanding of the changing geographic distribution of hepC, and, by proxy, the underlying epidemic opioid.